INDIGO Biosciences has been providing screening services for companies in the pharmaceutical, biotechnology, food, agriculture, and nutraceutical industries, as well as government agencies and academic researchers for over 15 years.
We are committed to providing results that help inform your research efforts and offer complimentary study design consultation as part of our service process. INDIGO’s luciferase reporter assay screening services include a positive control reference compound and “vehicle” control for every experiment. At the completion of a study, we provide you with a formal study report, as well as all data files. Our scientists are also available to provide a comprehensive review of the results with you once your service study is complete. View the list of luciferase reporter assays we offer below to begin designing your next service study.
Don’t see the receptor you need? Learn about our custom assay development services.
Many labs are interested in cross-species comparisons, especially contrasting human nuclear receptor activity to common laboratory animals. Determining a drug candidate’s cross-activity with human xenobiotic-sensing receptors provides important early indications of that drug’s potential for downstream drug-drug interactions. With animal studies required by the FDA, selecting the animal model that provides the most representative human-surrogate is critical to assessing a potential drug’s likelihood of unwanted effects. Cell-based assay models are crucial to help make this determination prior to entering ADMET studies.
With more than 30 ortholog assays - including rat, mouse, rabbit, dog, monkey, and zebrafish - available as kits and/or services, and others available for custom development, INDIGO helps researchers screen the right animal, before trial.
|Product Family||Cyn Monkey||Dog||Mouse||Rabbit||Rat||Zebrafish|
|Aryl Hydrocarbon Receptor||mAhR||rAhR||zAhR|
|Constitutive Androstane Receptor||mCAR|
|Estrogen Receptor Alpha||rERα||zERα|
|Estrogen Receptor Beta||rERβ|
|Farnesoid X Receptor||cFXR||dFXR||mFXR||rFXR|
|Liver X Receptor Alpha||mLXRα||rLXRα|
|Liver X Receptor Beta||mLXRβ||rLXRβ|
|Peroxisome Proliferator-Activated Receptor Alpha||cPPARα||dPPARα||mPPARα||rPPARα|
|Peroxisome Proliferator-Activated Receptor Beta/Delta||cPPARβ/δ||dPPARβ/δ||mPPARβ/δ||rPPARβ/δ|
|Peroxisome Proliferator-Activated Receptor Gamma||cPPARγ||m/rPPARγ||m/rPPARγ||zPPARγ|
|Pregnane X Receptor||cPXR||dPXR||mPXR||rPXR|
|Retinoic Acid Receptor Alpha||zRARαa|
|RAR-related Orphan Receptor Gamma||mRORγ||rRORγ|
|Thyroid Hormone Receptor Beta||zTRβ|
The emergence of liver toxicity is major reason for the termination of clinical drug trials, as well as post-market withdrawal of approved drugs. This assay for in vitro screening for drug-induced hepatotoxicity allows researchers to rapidly identify those compounds that induce liver toxicity. Learn more.
Determining if a drug candidate will have incidental interactions with P-Glycoprotein (P-gp, aka MDR-1, or ABCB1) is an important component of the safety assessment process. A drug that is either a substrate or inhibitor of MDR1 transporter activity can significantly alter the rate of absorption, distribution, metabolic conversion, and eventual excretion of co-administered drugs, thereby shifting their therapeutic effects and toxicologic profiles. Because of this, assessing a new drug's potency as an interactor with P-gp, and thus its potential liability for inducing downstream drug-drug interactions, is mandated by the FDA. Our assay for the assessment of MDR1 drug interaction allows for the rapid assessment of drug candidates as either inhibitors, substrates, or non-substrates of P-gp, and make critical decisions about potential drug candidates with confidence. Learn more.
Assessing drug-induced changes in the expression of Cytochrome P450 (CYP) genes provides a reliable predictive indicator of altered metabolic activity in vivo. It is estimated that CYPs are involved in 70% to 80% of drugs currently on the market, making understanding their metabolic actions crucial to the drug development process. Our gene expression assay utilizes upcyte® hepatocytes to assess drug-induced changes in the expression of seven clinically relevant CYPs: CYP3A4, CYP1A1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1. Learn more.